2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Infusion, Non-Biological Therapies, Chemotherapy, Pharmacology, Adverse Events, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Practice Models, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Measurable Residual Disease, ALL, Research, Translational Research, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

1537 Safety and feasibility of replacing pegaspargase with recombinant erwinia asparaginase (Rylaze®) during induction therapy for adults with newly diagnosed ALL and high risk features for asparaginase toxicities: An interim analysis from Phase 2 study

Ibrahim Aldoss, MD, Hoda Pourhassan, MD2, Jianying Zhang, PhD3, Wendy Stock, MD4, Emily Curran, MD5, Mark Blaine Geyer, MD6, Jessica Leonard I, M.D.7, Vaibhav Agrawal, MD8, Brian John Ball, MD, MS9, Idoroenyi Amanam, MD10, Tamer Othman, MD11, Katrin Tiemann12, Diana Oganesyan, NP, RN13, Jose Tinajero, PharmD14, Tibor Kovacsovics, MD15, Melisa Stricherz, PharmD, BCOP16, Anjali Sharma17, Stefan Faderl, MD18, Anthony Selwyn Stein, MD19, Guido Marcucci, MD20, Vinod Pullarkat, MD21
1 City of Hope National Medical Center, Duarte, California, United States
2 City of Hope National Medical Center, Duarte, California, United States
3 City of Hope National Medical Center, Duarte, California, United States
4 University of Chicago, Chicago, Illinois, United States
5 University of Cincinnati, Cincinnati, Ohio, United States
6 Memorial Sloan Kettering Cancer Center, New York, New York, United States
7 Oregon Health & Science University, Portland, Oregon, United States
8 City of Hope National Medical Center, Duarte, California, United States
9 City of Hope National Medical Center, Duarte, California, United States
10 City of Hope National Medical Center, Duarte, California, United States
11 City of Hope Orange County Lennar Foundation Cancer Center, Irvine, California, United States
12 City of Hope National Medical Center, Duarte, California, United States
13 City of Hope National Medical Center, Duarte, California, United States
14 City of Hope National Medical Center, Duarte, California, United States
15 City of Hope Cancer Center Phoenix, Goodyear, Arizona, United States
16 Jazz Pharmaceuticals, Dublin, Ireland
17 Jazz Pharmaceuticals, Dublin, Ireland
18 Jazz Pharmaceuticals, Dublin, Ireland
19 City of Hope National Medical Center, Duarte, California, United States
20 City of Hope National Medical Center, Duarte, California, United States
21 City of Hope National Medical Center, Duarte, California, United States

Background: Asparaginase (ASP)-containing regimens are recommended for young adults with newly diagnosed acute lymphoblastic leukemia (ALL). However, ASP-related toxicities commonly result in early discontinuation during therapy. Hepatotoxicity, the most frequent ASP-related toxicity, typically occurs during induction and can potentially interrupt ALL-directed therapy early in the treatment course. Older and obese patients (pts) are at particularly high risk, with up to 60% experiencing grade (G) ≥3 hepatotoxicity and a median time to recovery to G1 of approximately two weeks. The recombinant Erwinia ASP (Rylaze®) has a relatively short half-life, and it is approved as replacement therapy for pts who experience hypersensitivity reactions to E. coli–derived ASP products and may be associated with a lower incidence of high grade hepatotoxicity.

Methods: We designed a multicenter phase 2 study with a safety lead-in (SLI) to evaluate recombinant Erwinia ASP substitution for long-acting ASP during induction cycle using the CALGB 10403 backbone. Eligible pts included newly diagnosed B- or T-cell ALL/lymphoblastic lymphoma who were either 18–39 years old with body mass index (BMI) ≥30 kg/m² or 40–54 years (yr) old regardless of BMI. Recombinant Erwinia ASP was administered intramuscularly at standard 25 mg/m2 dose every 48 hours for seven doses without capping beginning on day 4 of induction. Pts completing induction were eligible to receive C10403 consolidation with recombinant Erwinia ASP. Ursodiol was administered prophylactically; however, levocarnitine was not. None of the reported patients received prophylactic anticoagulation. The primary endpoint of the SLI cohort was safety and tolerability. For the overall study population the primary endpoint is the proportion of pts who develop G ≥3 hepatotoxicity during induction that fails to resolve to G≤1 within 14 days. Key secondary endpoints include incidence and severity of other ASP-related toxicities, complete remission (CR)/CR with incomplete hematologic recovery (CRi) and measurable residual disease (MRD)-negative rates, and nadir asparaginase activity (NAA).

Results: As of July 23, 2026, a total of 18 pts were enrolled (6 on SLI and 12 on the expansion) and completed the induction phase. The median age was 41 yr (range, 21–52), with 10 pts (56%) aged ≥40 yr. The median BMI was 33.6 kg/m² (range, 19–52.9), and 14 pts (78%) had BMI ≥30 kg/m². Six pts (33%) met both high-risk criteria of obesity and age ≥40 yr. Most pts had B-cell disease (n=14, 78%) and adverse-risk genomic features according to NCCN criteria (n=13, 72%).

No unacceptable toxicity was observed in either the SLI cohort or the overall study population. Fifteen (83%) pts completed all 7 doses of recombinant Erwinia ASP during induction and 3 pts received 6 out of 7 doses due to G3 transaminitis (n=1), elevated lipase >2× upper limit of normal (n=1), and suspected cavernous sinus thrombosis that was subsequently ruled out (n=1).

During induction, no pt developed clinical pancreatitis or G≥3 hyperbilirubinemia; G2 hyperbilirubinemia was only observed in 4 (22%) pts, and 56% of pts did not develop any hyperbilirubinemia. Only 1 (6%) pt experienced G3 transaminitis that resolved after 5 days. Six pts developed thrombosis (4 were catheter-related), all were G1 (n=1) and G2 (n=5) events. G ≥3 hypofibrinogenemia and hypertriglyceridemia occurred in 5 (28%) and 2 (11%) pts, respectively.

NAA was measured before recombinant Erwinia ASP dose 6 or 7 and was therapeutic (≥ 0.1 IU/mL) in 94% (17/18) of pts, with a median activity level of 0.305 (range: 0.117-0.909) IU/mL. CR/CRi rate following induction was 89% (16/18), and MRD-negative rate by flow cytometry post induction was 62.5% (n= 10) among responders. Seven pts (39%) subsequently received consolidation therapy and all 5 pts who completed consolidation achieved MRD- CR.

Conclusion: Substitution of long-acting E. coli-derived ASP with recombinant Erwinia ASP in a pediatric-inspired regimen for adults at high risk for ASP-related toxicities (older age and/or obesity) was safe and feasible. This approach was associated with a low incidence of severe hepatotoxicity, no G≥3 hyperbilirubinemia, adequate therapeutic ASP activity in nearly all pts, and high remission rates despite the predominance of adverse-risk genomic features. These findings support further evaluation of recombinant Erwinia ASP as an alternative frontline ASP strategy in high-risk adult pts with ALL.

Ibrahim Aldoss, MD: Amgen - Honoraria; Pfizer - Honoraria; Allotera - Research Funding; Jazz Pharmaceuticals - Research Funding; Novartis - Research Funding; MacroGenics - Research Funding; AbbVie - Research Funding; Autolus - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); Menarini Stemline - Consultancy (Includes expert testimony); Amgen - Consultancy (Includes expert testimony); Syndax Pharmaceuticals, Inc. - Consultancy (Includes expert testimony); Jazz Pharmaceuticals - Consultancy (Includes expert testimony); Acentage - Consultancy (Includes expert testimony); Kite - Consultancy (Includes expert testimony); Adaptive - Consultancy (Includes expert testimony); Allotera - Consultancy (Includes expert testimony)